Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Mitsuoka

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Pharmacology Research & Perspectives|January 25, 2017
Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using <sup>11</sup>C-MDGKeisuke Mitsuoka, Yuka Hayashizaki, Yoshihiro Murakami, et al.
Nuclear Medicine and Biology|November 13, 2012
Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse modelYoshihiro Murakami, Takahiro Matsuya, Aya Kita, et al.
Anticancer Research|November 14, 2013
Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomographyHiroshi Fushiki, Sosuke Miyoshi, Akihiro Noda, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2008
Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporterKeisuke Mitsuoka, Sosuke Miyoshi, Yukio Kato, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 13, 2012
Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximabAya Kita, Keisuke Mitsuoka, Naoki Kaneko, et al.
European Journal of Pharmacology|February 4, 2014
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese ratsMasanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Pharmacology Research & Perspectives|January 25, 2017
Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using <sup>11</sup>C-MDGKeisuke Mitsuoka, Yuka Hayashizaki, Yoshihiro Murakami, et al.
Nuclear Medicine and Biology|November 13, 2012
Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse modelYoshihiro Murakami, Takahiro Matsuya, Aya Kita, et al.
Anticancer Research|November 14, 2013
Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomographyHiroshi Fushiki, Sosuke Miyoshi, Akihiro Noda, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2008
Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporterKeisuke Mitsuoka, Sosuke Miyoshi, Yukio Kato, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 13, 2012
Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximabAya Kita, Keisuke Mitsuoka, Naoki Kaneko, et al.
European Journal of Pharmacology|February 4, 2014
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese ratsMasanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki, et al.
Pageof 2